Freedman, Mark S

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., Correale, J., Fazekas, F., Filippi, M., Freedman, M. S., et al. (2018) · The Lancet Neurology

Multiple Sclerosis Research StudiesClinical Reasoning and Diagnostic Skills

Cited by 8,167

Defining the clinical course of multiple sclerosis: The 2013 revisions

Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology

Multiple Sclerosis Research StudiesPsoriasis: Treatment and Pathogenesis

Cited by 3,177

Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria

Montalban, X., Lebrun-Frénay, C., Oh, J., Arrambide, G., Moccia, M., Pia Amato, M., Amezcua, L., Banwell, B., Bar-Or, A., Barkhof, F., et al. (2025) · The Lancet Neurology

Multiple Sclerosis Research StudiesPolyomavirus and related diseases

Cited by 551

Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial

Kappos, L., Fox, R. J., Burcklen, M., Freedman, M. S., Havrdová, E. K., Hennessy, B., Hohlfeld, R., Lublin, F., Montalban, X., Pozzilli, C., et al. (2021) · JAMA Neurology

Multiple Sclerosis Research StudiesSphingolipid Metabolism and Signaling

Cited by 228